EGFR and lung carcinoma: However, a second problem is that with the exception of treating EGFR mutant lung cancers, the majority of examples of the use of EGFR inhibitors, and most other TKIs have been in combination with a second agent, most typically a standard cytotoxic agent (Geyer et al., 2006).